[THE INVESTOR] Seegene announced on Sept. 26 that its Italian subsidiary Arrow Diagnostics has signed a five-year contract to supply sexually transmitted diseases and human papillomavirus detectors worth 7.5 million euros (US$8.43 million) to 17 state hospitals in Italy’s Toscana region.
The South Korean company will provide molecular testers that can simultaneously test multiple sexually transmitted infections (AnyplexII STI-7) and multiple genotypes of human papillomavirus (AnyplexII HPV28) with a single test.
By Hwang You-mee (
glamazon@heraldcorp.com)
